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Abstract
Synthesis of acetylcholine (ACh) by non-neuronal cells is now well established and plays diverse
physiologic roles. In neurons, the Na+-dependent, high affinity choline transporter (CHT1) is
absolutely required for ACh synthesis. By contrast, some non-neuronal cells synthesize ACh in the
absence of CHT1 indicating a fundamental difference in ACh synthesis compared to neurons. The
aim of this study was to identify choline transporters, other than CHT1, that play a role in non-
neuronal ACh synthesis. ACh synthesis was studied in lung and colon cancer cell lines focusing
on the choline transporter-like proteins, a five gene family (CTL1-5). Supporting a role for CTLs
in choline transport in lung cancer cells, choline transport was Na+-independent and CTL1-5 were
expressed in all cells examined. CTL1,2,&5 were expressed at highest levels and knockdown of
CTL1,2&5 decreased choline transport in H82 lung cancer cells. Knockdowns of CTL1,2,3&5 had
no effect on ACh synthesis in H82 cells. By contrast, knockdown of CTL4 significantly decreased
ACh secretion by both lung and colon cancer cells. Conversely, increasing expression of CTL4
increased ACh secretion. These results indicate that CTL4 mediates ACh synthesis in non-
neuronal cell lines and presents a mechanism to target non-neuronal ACh synthesis without
affecting neuronal ACh synthesis.
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Introduction
Synthesis and secretion of acetylcholine (ACh) to act as an autocrine or paracrine hormone
by non-neuronal tissues is now well established (Wessler and Kirkpatrick 2008). Choline
acetyltransferase (ChAT) and ACh synthesis has been demonstrated in airway epithelial
cells (Klapproth et al. 1997; Proskocil et al. 2004; Wessler and Kirkpatrick 2008), colon
epithelial cells (Porter et al. 1996; Cheng et al. 2008; Yajima et al. 2011), keratinocytes
(Kurzen et al. 2007), glia (Wessler et al. 1997), lymphocytes (Kawashima and Fujii 2000),
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and ovarian follicular cells (Mayerhofer and Kunz 2005) among other cell types. Non-
neuronal ACh plays multiple physiologic and pathologic roles, affecting growth,
development, secretion and ciliary movement among many actions (Lips et al. 2007;
Wessler and Kirkpatrick 2008; En-Nosse et al. 2009; Novotny et al. 2011; Hollenhorst et al.
2012). In both lung cancer and colon cancer, ACh acts as an autocrine growth factor for
cancer growth and development (Song et al. 2003; Song et al. 2007; Song et al. 2008). The
wide-spread expression of ACh in non-neuronal tissues makes it important to understand
how non-neuronal ACh synthesis differs from neuronal ACh synthesis.
There are clear similarities and differences between neuronal and non-neuronal cholinergic
signaling. Both neuronal and non-neuronal cell types express choline acetyltransferase, the
vesicular acetylcholine transporter, cholinesterases, nicotinic and muscarinic receptors
(Proskocil et al. 2004; Wessler and Kirkpatrick 2008). Regulation of ACh secretion is
obviously different as non-neuronal cells generally are not excitable and secretion is not
triggered by action potentials. Another clear difference is transport of choline that is used for
ACh synthesis.
In neurons choline used for ACh synthesis is transported from extracellular spaces via a
Na+-dependent, high-affinity choline transporter (CHT1) (Apparsundaram et al. 2000;
Okuda et al. 2000) and in the absence of CHT1, neurons cannot synthesize ACh (Ferguson
et al. 2004). By contrast, colon epithelial cells (Yajima et al. 2011) and lung cancer cells can
synthesize ACh in the absence of CHT1 (Song et al. 2003; Song and Spindel 2008). Thus,
choline transport in non-neuronal cells cannot be solely dependent on CHT1 and must by
necessity utilize other choline transporters such as the recently described family of five
choline transporters designated as the choline transporter-like proteins 1–5 (CTL1–5)
(O’Regan et al. 2000; Traiffort et al. 2005). The CTLs are Na+-independent and have an
intermediate-affinity for choline and hemicholinium-3 (HC-3) as compared to CHT1
(O’Regan et al. 2000; Inazu et al. 2005; Traiffort et al. 2005). CTL1 in particular has been
shown to transport choline in renal tubule epithelia (Yabuki et al. 2009), keratinocytes
(Uchida et al. 2009), neuroblastoma (Machova et al. 2009; Yamada et al. 2010) and lung
adenocarcinoma cells (Nakamura et al. 2010). CTL2 has also been shown to transport
choline in lung adenocarcinoma cells (Nakamura et al. 2010). CTL3 has recently been
demonstrated to be expressed in neutrophils and has been identified as the human neutrophil
alloantigen-3a (Greinacher et al. 2010). While it has been suggested that CTL1 may be
linked to non-neuronal ACh synthesis, this has only been proposed on the frequent co-
expression of CTL1 with non-neuronal ACh (Yamada et al. 2010).
We thus undertook to determine which of the CTL’s is positively linked to ACh synthesis in
two different non-neuronal systems, examining both small cell lung carcinoma (SCLC) cells
using the H82 cell line that synthesizes ACh but does not express CHT1 and the H508 colon
cancer cell line that similarly synthesizes ACh but does not express detectable levels of
CHT1. This was done by a combination of pharmacologic characterization of choline
transport and characterizing the effect of knockdown of the different CTL’s and expression
of CTL4 on ACh synthesis. In this paper, we show that of the CTLs, only CTL4 appears
positively linked to ACh synthesis in two different non-neuronal cell types.
Materials and Methods
Cell lines and tumors
Small cell lung carcinoma cell lines H417, H592, H69, H82, H146, H345, and H1694 cell
lines were obtained from ATCC. HA-E, SV-E, MO-A, RG-1 and YR-A cell lines were
established as previously described (Campling et al. 1992). H82 cells were maintained in
RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with 1% fetal bovine serum,
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5 μg/ml insulin, 5 μg/ml transferrin, 5 ng/ml sodium selenite. The medium for maintaining
other SCLC cell lines was RPMI1640 containing 10% fetal calf serum. Archival samples of
SCLC were obtained from the Department of Pathology in Oregon Health & Sciences
University and from the Department of Neuroscience in University of Pennsylvania. Colon
cancer cell lines HT-29, H747, H508, SNU-C1, WiDr, Caco-2 and HCT-15 were obtained
from ATCC and maintained as suggested by ATCC.
PCR
RT-PCR and realtime PCR were used to detect mRNAs for CHT1 and the CTLs in SCLC
cell lines and tumors. RNA was prepared and PCR performed as previously described (Song
et al. 2003). Realtime assays were run in duplex using 18s RNA as an internal standard.
Primers used for PCR and realtime-PCR are listed in supplement table 1.
CTL knockdown with siRNAs
On-Target Plus smart pool siRNAs against CTL1, 2, 3, 5 and CHT1 were purchased from
Dharmacon (Chicago, IL, USA). SiRNA against CTL4 (sRNA ID# s37329) was from
Ambion (Austin, TX, USA). SiRNAs were transfected according to the manufacturer’s
protocol, with DharmaFECT 1 (Dharmacon), at a concentration of 100 nM and treated cells
were used at approximately 96 hours post transfection.
CTL4 lentiviral transduction
The CTL4 cDNA was obtained from the image consortium and subcloned into the lentiviral
shuttle vector pLVI-IRES which contains a CMV promoter to drive cDNA expression and a
bicistronic-expressed GFP marker. Lentivirus was prepared and titrated as previously
described (Dissen et al. 2009). H82 cells were infected at a ratio of 5 transforming units per
cell in the presence of polybrene 0.16 μg/ml. Colon cancer cells were similarly infected but
without polybrene. One week post infection, cells were sorted by flow cytometry
(FACSCalibur, BD Bioscience, San Jose, CA) and used for studies described hereafter.
ACh and ChAT analysis
To investigate effects of choline concentration on ACh synthesis and secretion, 24-well
plates were seeded with H82 cells at a concentration of 5 × 105 cells per well in 1 ml and
different concentrations of choline chloride (Sigma, St. Louis, MO, USA) added. After
plating, in order to inhibit cholinesterase activity, 50 μM neostigmine (Sigma) was
immediately added to each well. The concentration of choline in unsupplemented
RPMI-1640 medium is 20 μM. Additional choline at concentrations of 30, 100, 300 and
1000 μM respectively were added into the wells of cell culture plates and incubated for 24 h.
After incubation, cells were centrifuged and supernatants quick frozen and stored at −80 °C.
ACh was extracted from cell pellets with 90% methanol in 0.1 M formic acid.
To investigate effects of individual CTL knockdown or CTL4 transduction, the lung or
colon cancer cells were harvested and incubated with baseline choline and 50 μM
neostigmine after knockdown of each CTL or after CTL4 transduction as described as
above. To measure Na+ dependence of ACh synthesis, 3 × 106 H82 cells per well were
incubated in Na+ buffer or Na+-free buffer. For Na+-free buffer, NaCl was replaced with an
equimolar concentration of N-methyl-D-glucamine chloride as described by Inazu et al
(Inazu et al. 2005). Samples for ACh assay were harvested after 3 h incubation.
Acetylcholine was measured by HPLC with enzyme-coupled electrochemical assay as
previously described (Song et al. 2003) or by mass spectrometry (4000 Q TRAP™ LC/MS/
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MS System, Applied Biosystems, Foster City, CA, USA) using D4-ACh as an internal
standard, as described by Philips et al (2010). Results by both methods were similar.
Choline uptake assay
Choline uptake was measured with [3H]choline (86Ci/mM, PerkinElmer, Boston, USA) as
described by (Inazu et al. 2005). To measure choline uptake, H82 cells were harvested and
washed twice with choline-free uptake buffer, consisting of 125 mM NaCl, 4.8 mM KCl, 1.2
mM CaCl2 and 1.2 mM KH2PO4, 5.6 mM glucose, 1.2 mM MgSO4 and 25 mM HEPES (pH
to 7.4). 5 × 105 H82 cells were incubated with 20 nM [3H]choline at room temperature for
different time periods (5, 10, 20, 40, and 80 min). Uptake was terminated by adding ice-cold
buffer and then cells were centrifuged and washed five times with ice-cold buffer. Cells
were lysed in 0.4 ml of 1% SDS/0.2 M NaOH, and cellular incorporation of [3H]choline was
determined by scintillation counting. Nonspecific choline uptake was determined by adding
1 mM hemicholinium-3 (HC-3). For choline uptake saturation analysis in the Na+ buffer or
Na+-free buffer, 20 nM [3H]choline plus different concentrations (0.78, 1.56, 3.125, 6.25,
12.5, 50 and 100 μM) of choline were added. To measure the effect of specific CTL1, 2, 4
and 5 knockdown on choline transport, H82 cells were harvested 4 days after transfection
and resuspended in Na+-free buffer for choline uptake analysis. [3H]-choline uptake data
was normalized by protein measurement with BCA assay (Thermo Scientific, Rockford,
USA).
Cell proliferation
H82 cells were used for evaluation of SCLC cell growth. H82 cells were plated at 5,000
cells/well in 96-well culture plates and increasing concentrations of choline were added to
the wells. For characterization of the role of cholinergic receptors, either the nAChR
antagonist mecamylamine at 10−6 and 10−5 M or the mAChR antagonist atropine at 10−6
and 10−5 M were added to wells containing 10−3.5 M choline. Cell number after 9 days was
then measured using the MTS assay as previously described (Song et al. 2003). For
characterization of the effect of CTL knockdown, cells were plated in 96-well plates and
siRNAs (100 nM final concentration) and DharmaFECT 1 were added and 4 days after
transfection, cell proliferation was assayed with CellTiter-Blue™ reagent (Promega,
Madison, WI, USA).
Statistical analysis
All data are presented as Mean ± SE. Data for cell growth and choline uptake, ACh
secretion were analyzed by ANOVA with Newman-Keuls multiple-comparison tests. The
effects of CTL4 transduction on choline transport and ACh secretion were analyzed by two
sample t-test. Kinetic parameters were calculated by non-linear regression methods using
Prism (GraphPad Software, Inc., San Diego, CA, USA).
Results
ACh secretion by H82 SCLC cells is dependent on media choline concentration
As shown in figure 1, ACh secretion by lung cancer cells is directly affected by media
choline levels. ACh secretion was increased in a dose-dependent manner by increased
concentration of choline in the media (R2 =0.945, p <0.05) (Fig. 1A, B). Addition of
neostigmine significantly increased ACh levels, showing the presence of cholinesterase in
the media, and further confirming the specificity of the ACh assay. Realtime PCR assay of
ChAT mRNA levels showed no changes in ChAT mRNA levels with increased choline
levels, and assay of ChAT enzymatic activity also showed no changes with increased
choline levels (data not shown). Ninety percent of ACh synthesized by H82 cells was
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constitutively released as determined by measuring levels of ACh in cell pellets (Fig. 1C).
Thus, ACh levels in the medium accurately reflect ACh synthesis and are dependent on
choline transport into the cell.
Choline transport and ACh synthesis by H82 cells
As shown in Table 1, H82 cells as well as the majority of SCLC cell lines tested do not
express CHT1; therefore SCLC must utilize other choline transporters for ACh synthesis. To
begin to characterize the transporters involved in choline transport into lung cancer cells,
kinetics of [3H]choline uptake was examined. As shown in Fig. 2A, [3H]choline uptake in
H82 cells was increased in a time-dependent manner in 125 mM Na+ buffer. Non-specific
[3H]choline uptake was less than 10% of total [3H]choline uptake in the presence of 1 mM
HC-3 at all choline concentrations tested. Based on these findings, subsequent saturation
curve experiments were performed using an uptake period of 20 min in both the presence
and absence of Na+. Kinetic analysis of specific choline uptake data in 125 mM Na+ buffer
and Na+-free buffer yielded Michaelis-Menton constant (Km) of 10.2 ± 3.2 μM and 8.2 ±
1.6 μM and Maximal velocity (Vmax) 90.3 ± 8.6 and 82.2 ± 4.8 pmol/20 min, respectively.
The close kinetic parameters in both 125 mM Na+ buffer and Na+-free buffer show that Na+
does not significantly affect choline transport and that choline uptake in H82 cells is
mediated by a Na+-independent mechanism. This further rules out a role high affinity
choline transporter CHT1 which is Na+ dependent.
The Eadie-Hofstee plot (Fig. 2B, inset) shows a single line in both 125 mM Na+ buffer (r2
=0.99, p<0.001) and Na+-free buffer (r2=0.96, p<0.001), suggesting that the majority of
choline uptake into H82 cells is primarily mediated by a single class of transporters. Linkage
to ACh synthesis appears more complicated since as shown in Fig. 2C, ACh secretion was
decreased by 30% in Na+-free buffer compared to buffer that included Na+ and by 50% in
the presence of HC-3 compared to incubation without HC-3. This suggests that the primary
choline transporter specifically linked to ACh is Na+-independent and HC-3 sensitive, but
that other transporters may also link to ACh synthesis.
The CTLs transport choline in SCLC
The data above showing that choline transport in SCLC was Na+-independent and sensitive
to HC-3 is consistent with the known pharmacology of the CTLs (O’Regan et al. 2000;
Inazu et al. 2005; Traiffort et al. 2005) therefore suggesting a role for the CTL’s in choline
transport in SCLC. On this basis, RT-PCR was performed to characterize the expression of
the CTLs in a panel of SCLC cell lines and tumors. As shown in Table 1, all five subtypes of
CTL could be detected by conventional RT-PCR in all SCLC cell lines tested and tumors,
except for H146 and H592 which lacked CTL4. By contrast, CHT1 could not be detected in
more than half of SCLC tumors and cell lines tested. Realtime PCR showed levels of CTL4
was substantially lower than levels for CTL1, 2 and 5 and CTL3 was essentially
undetectable (Table 1). Increasing levels of choline in the cell culture medium did not
increase levels of the CTL mRNAs.
Knockdown of CTL1, 2 and 5 significantly decreased choline transport in H82 cells,
demonstrating the role of CTL1, 2 and 5 in choline transport in SCLC (Fig. 3A,B). No effect
on choline transport was seen by knockdown of CTL4 which is consistent with its lower
levels compared to CTL1, 2 and 5. The effect of CTL3 knockdown on choline transport was
not measured because of its very low levels of expression.
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Choline transporter-like protein 4 is linked to ACh synthesis and secretion in lung cancer
cells
To determine if a specific CTL subtype was linked to ACh synthesis in SCLC, the effect of
knockdown of each CTL subtype on ACh secretion was tested in H82 cells. As shown in
Fig. 3C only the knockdown of CTL4 significantly reduced ACh secretion. The CTL4
knockdown also significantly reduced the increase in ACh secretion caused by increased
media choline (data not shown). Surprisingly, knockdown of CTL 1 and 2 actually increased
ACh secretion by H82 cells (Fig. 3C). CHT1 which is not expressed in H82 cells served as a
negative control, and as expected, had no effects on ACh secretion (Fig. 3C). Specificity of
isoform knockdowns was confirmed by measuring levels of the other transporters and
detecting no changes in the non-targeted forms (Fig. 3A).
The linkage between CTL4, choline transport and ACh synthesis was confirmed by
transduction of H82 cells with a lentivirus expressing CTL4 (Fig. 4). CTL4 transduction
significantly increased choline uptake in the presence of 20 nM and 10 μM choline (Fig.
4A). Importantly, as shown in figure 4B, CTL4 transduction significantly increased ACh
secretion in H82 cells and this effect was enhanced by higher concentrations of choline.
Levels of CTL4 mRNA in the transduced cells were increased more than 200-fold and levels
of the other CTL’s were not affected (Fig. 4C).
Choline transporter-like protein 4 is also linked to ACh synthesis and secretion in colon
cancer cell lines
To generalize the role of CTL4 in non-neuronal ACh synthesis we studied a second cell type
which is well established to secrete ACh, notably colonic epithelial cells as exemplified by
colon carcinoma cell lines. As shown in figure 5, colon cancer cell lines express both CTL1
and CTL4, though colon cancer cells express significantly higher levels of CTL4 than do
lung cancer cells (Fig 5A,B). Levels of CHT1 in colon cancer cells were essentially
undetectable (data not shown). As shown in figure 5C, CTL4 knockdown in H508 colon
cancer cells which have high levels of CTL4 significantly decreased both intracellular and
secreted ACh, while knockdown of CTL1 and CHT1 had no significant effect on ACh
synthesis and secretion. As shown in figure 5D, expression of CTL4 in Caco-2 colon cancer
cells which have low levels of CTL4 significantly increased intracellular ACh levels, though
secretion of ACh into the media was not significantly changed.
Targeting CTL4 can modulate cell growth
As an illustration of the potential importance of CTL4 as a way to target non-neuronal ACh
synthesis, we investigated the ability of CTL4 knockdown as a way to modulate growth of
lung cancer cells. First as shown in figure 1C, ACh secretion by H82 lung cancer cells is
increased in a concentration-dependent manner by increased extracellular choline. In turn, as
shown in Fig. 6A, increased choline significantly increased H82 cell proliferation in a
concentration-dependent manner. This increase in proliferation appears to be mediated by
secreted ACh as it was reduced by both the muscarinic antagonist atropine (Fig. 6B) and the
nicotinic antagonist mecamylamine (Fig 6C). Consistent with the potential importance of
CTL4 as a way to specifically target effects of non-neuronal ACh, CTL4 knockdown
significantly decreased the growth of H82 cells (Fig. 6D). By contrast, knockdown of CTL1
and CTL5 did not significantly affect cell growth (Fig. 6D). Increased choline by itself did
not affect CTL levels in either lung or colon carcinoma cells (Fig 6E,F).
Discussion
Acetylcholine is synthesized from choline and acetyl-CoA by the action of ChAT. For ACh
synthesis to proceed, choline must be transported into the cell by a choline transporter that is
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linked in some manner to ChAT. Choline is an organic cation and does not freely cross cell
membranes. Its uptake from extracellular spaces requires specific choline transporters
present on cell membranes. In neurons, the high affinity choline transporter CHT1 is
absolutely required for ACh synthesis (Apparsundaram et al. 2000; Okuda et al. 2000;
Ferguson et al. 2004), but as shown in table 1, H82 cells and the majority of SCLC cell lines
examined do not express CHT1 yet synthesize ACh (Song et al. 2003); therefore, lung
cancers must utilize a different choline transporter than CHT1 for ACh synthesis. This is not
unique to lung cells as colon crypt cells also lack CHT1 but synthesize ACh (Yajima et al.
2011). Thus two quite different types of epithelial cells do not utilize CHT1 for choline
transport for ACh synthesis and therefore rely on other choline transporters for this purpose.
Multiple choline transporters have been identified in humans and other species (Kleinzeller
et al. 1994; Pfeil et al. 2003), therefore the purpose of this study was to begin to identify the
choline transporters that are linked to non-neuronal ACh synthesis.
As shown in figure 1, ACh secretion by H82 SCLC cells is directly related to media choline
concentration (Fig. 1A, 1B and 1C) and there is a clear correlation between choline
concentration and ACh secretion (Fig. 1D). The increased ACh secretion caused by
increased choline levels was not caused by increased ChAT activity, nor was the increase
caused by changes in cholinesterase levels since the changes were seen in the presence of
neostigmine, a cholinesterase inhibitor. In this regard, H82 cells are similar to neurons
where choline also increases ACh synthesis (Ulus et al. 1989) although obviously other
significant differences such as the mechanisms underlying ACh secretion are present (Song
and Spindel 2008). This is reflected by the relatively low ACh levels in H82 cell pellets in
which ACh in cell pellets is only 1/10 as much as is in the media, suggesting a degree of
constitutive secretion.
Recently, a new family of intermediate affinity choline transporters, the choline transporter-
like proteins, (CTLs) has been shown to be widely expressed in mammalian tissues. Five
CTL genes have been described (CTL1-5) and complex alternative spicing also occurs
(O’Regan et al. 2000; Traiffort et al. 2005). In human and rat, CTL1-4 mRNA are mainly
detected in peripheral tissues, while CTL1 is also widely expressed throughout the nervous
system (Traiffort et al. 2005). The CTLs are Na-independent and inhibited by HC-3 at
millimolar concentrations as opposed to the nanomolar inhibition of CHT1 by HC-3. This
pharmacology of the CTLs is similar to what we observed in H82 cells in which choline
transport was also primarily Na+-independent with a Km of 8.2 μM and was inhibited by
μM concentrations of HC-3 (Fig. 2). Consistent with a role for the CTL’s in choline
transport in lung cells, RT-PCR showed that CTL1-5 are expressed in essentially all lung
cancer cell lines tested (Table 1). Quantitation by real-time PCR showed abundant levels of
CTL1, 2 and 5 in all cell lines and tumors while levels of CTL3 and 4 were significantly
lower. This distribution is similar to that reported by Tomi et al who found levels of CTL3
and CTL4 were 100-fold lower than levels of CTL1 in rat retinal capillary endothelial cells
(Tomi et al. 2007).
The roles of CTL 1, 2 and 5 in transporting choline in H82 cells was confirmed by sRNA
knockdown, in which knockdown of each of those transporter subtypes decreased choline
transport by ~30% (Fig. 3B). This confirms that the multiple CTLs expressed by SCLC can
indeed transport choline. Knockdown of CTL4 did not affect choline uptake, suggesting
CTL4 does not significantly contribute to total choline uptake consistent with its lower
levels of expression. Our findings are consistent with those of Nakamura al (Nakamura et al.
2010) who also saw a decrease in choline transport by knockdown of CTL1 and CTL2 in
A549 lung adenocarcinoma cells and Machova et al who showed CTL1 knockdown
decreased choline transport in neuroblastoma cells (Machova et al. 2009). Thus our and
others’ findings clearly demonstrate a role for the CTL’s in choline transport.
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To determine if one of the CTL’s was specifically linked to ACh synthesis in lung cells,
CTL1-5 were individually knocked-down with siRNAs. As seen in Figure 3C, knockdown
of CTL 1, 2, 3, 5 and CHT1 did not decrease ACh synthesis. Only the knockdown of CTL4
significantly reduced ACh synthesis and secretion. This suggests that in SCLC, of the 5
CTL’s, only CTL4 is specifically coupled to ACh synthesis; similar to CHT1 which in
neurons is specifically coupled to ACh synthesis. Confirming the linkage of CTL4-mediated
choline transport to ACh synthesis in lung cell lines, expression of CTL4 in H82 cells
increased both choline transport and ACh synthesis (Fig. 4A and 4B). An unexpected
finding was that ACh synthesis after knockdown of CTL1 and CTL2 actually increased. One
possible explanation is that in the absence of CTL1 and CTL2, more choline is transported
by CTL4 thus leading to increased ACh synthesis. Another possibility is that CTL1 and 2
play a role in ACh reuptake as has been proposed for the organic cation transporter N1
(OCTN1) (Pochini et al. 2011) and therefore the CTL1 and 2 knockdowns increased media
ACh levels by inhibiting reuptake.
It is interesting to note that stimulation of ACh secretion and cell growth occurs at choline
levels higher than the saturating levels for choline transport shown in figure 2. This suggests
that that CTL4 may have lower affinity for choline than some of the other CTL’s or reflect
the mechanism by which choline for ACh synthesis is segregated from the general pool of
intracellular choline.
To rule out the possibility that lung cancer cells are unique among non-neuronal cell types in
their use of CTL4 for ACh synthesis we examined a second epithelial cell type known to
synthesize ACh, namely colonic epithelial cells as exemplified by colon cancer cells which
have been clearly shown to synthesize ACh (Porter et al. 1996; Yajima et al. 2011). As
shown in figure 5B, 7 of 7 colon cancer cell lines expressed CTL4. CHT1 was generally
undetectable in these lines (data not shown). Colon cancer cells consistently expressed
higher levels of CTL4 than did lung cancer cells (Fig. 5B). Confirming the role of CTL4 in
ACh synthesis in colon cancer cells knockdown of CTL4 significantly decreased levels of
ACh synthesis and secretion in H508 colon cancer cells which express relatively high levels
of CTL-4 and CTL4 transduction increased levels of intracellular ACh in Caco-2 colon
cancer cells which express relatively low levels of CTL4. Increased levels of secretion of
ACh into the media in Caco-2 cells transduced with CTL4 was not seen which likely
represents the relatively low levels of ChAT that are expressed by those cells and thereby
likely limiting ACh synthesis. This finding confirms the role of CTL4 in two diverse types
of epithelial cells in non-neuronal ACh synthesis and suggests that CTL4 is likely involved
in ACh synthesis by cell types that do not depend on CHT1.
It is important to note that CTL-4 may not be the only choline transporter linked to non-
neuronal ACh synthesis. For example the organic cation transporter 1 (OCT1) has also been
suggested to play such a role as well as being involved in ACh secretory processes (Lips et
al. 2007; Yajima et al. 2011). Other choline or cation transporters may also turn out to be
linked to non-neuronal ACh synthesis role as well and there may be tissue specificity in the
choline transporters used for ACh synthesis in different tissues. The finding of the linkage of
CTL-4 to non-neuronal ACh synthesis suggests apparent compartmentalization of choline
transport and ACh synthesis. In neurons, compartmentalization appears to derive from
localization of CHT1 to synaptic vesicles, endosomes, or the cell membrane (Ribeiro et al.
2006; Cuddy et al. 2012). Whether similar localization of CTL4 in analogous compartments
(eg, secretory vesicles, endosomes or cell membrane) plays a role in non-neuronal ACh
synthesis remains to be determined. Regardless of the mechanism of linkage, it is clear that
not just any choline transporter will support non-neuronal ACh synthesis as knockdowns of
CTL1, 2, 5 and CHT1 did not affect ACh secretion in the cell lines tested.
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Identification of the choline transporters linked to non-neuronal ACh synthesis has clear
importance both for a fundamental understanding of the mechanisms of non-neuronal ACh
synthesis but also to provide a way to target non-neuronal ACh synthesis without targeting
neuronal ACh synthesis. An example is shown in figure 6 in which the growth of a lung
cancer cell line can be inhibited by knocking down levels of CTL4 while knockdown of
CTL1 or 5 had no effect on cell growth. This is consistent with the multiple reports that,
choline uptake is increased in lung cancers compared to normal cells (Ackerstaff et al. 2003;
Glunde et al. 2006) which may partially underlie the increased levels of ACh in lung cancer
compared to normal lung (Song et al. 2008; Song and Spindel 2008). The data shown in
figure 6 suggests that increased choline can stimulate cell proliferation through both
nicotinic and muscarinic mechanisms, and it is likely that increased choline also stimulates
cell growth secondary to increased phospholipid synthesis. These data also suggest that
other diseases found to be characterized by increased non-neuronal ACh synthesis could
also potentially be treated by CTL4 knockdown.
In summary our data shows that the choline transporter CTL4 appears to be specifically
linked to non-neuronal acetylcholine synthesis and secretion as exemplified by lung and
colon cancer cells. By contrast the choline transporters CHT1, CTL1, CTL2, and CTL5 do
not appear necessary for non-neuronal ACh synthesis and/or secretion. These findings
suggest some degree of functional linkage of CTL4 to ACh synthesis and secretion in non-
neuronal cells and that therefore, CTL4 can be targeted as a way to change non-neuronal
ACh secretion without affecting the choline transported in neurons by CHT1 that is needed
for neuronal ACh synthesis.
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CHT1 choline high affinity transporter
CTL choline-transporter like protein
mAChR muscarinic acetylcholine receptor
nAChR nicotinic acetylcholine receptor
SCLC small cell lung carcinoma
HC-3 hemicholinium-3
MAPK mitogen-activated protein kinase
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Choline increases ACh secretion by H82 SCLC cells. A. Choline significantly increased
ACh secretion by H82 cells in a concentration-dependent manner. Addition of the
cholinesterase inhibitor neostigmine (50 μM) resulted in increased levels of ACh in the
medium. Secretion represent total amount of ACh secreted by 500,000 cells over 24 hours.
B. There is a linear relationship between choline concentration and ACh secretion by H82
cells. Data are mean ± SE of 4 separate experiments. * p<0.05 versus no neostigmine; †
p<0.05 versus 20 μM choline + neostigmine. C. Relative levels of ACh in cells versus
medium. 500,000 H82 cells were cultured in standard medium (20 μM choline) in the
presence of neostigmine for 24 hours and levels of ACh in media and cell pellet measured.
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Na+-independent choline uptake and ACh synthesis by H82 cells. A. Time course of
[3H]choline (20 nM) uptake. Each point represents the mean ± SE of four experiments in
125 mM Na+ buffer. Non-specific [3H]choline uptake was determined in the presence of 1
mM hemicholinium-3 (HC-3). B. Choline uptake is Na+-independent in H82 cells. Substrate
saturation curves of choline uptake in 125 mM NaCl and Na+-free buffer were established as
described in the material and methods. Uptake of choline by H82 cells was measured for 20
min at increasing concentrations of choline. Non-specific choline uptake was also
determined by adding 1 mM HC-3. Inset: Eadie-Hofstee plots of the data. V, uptake rates in
pmol/mg/20min; S, choline concentration. Data are mean ± SE of six replicates in three
experiments. C. Effect of HC-3 and Na+-free buffer on ACh synthesis in H82 cells standard
medium (20 μM choline) in the presence of neostigmine. Each point represents the mean ±
SE of four replicates in two experiments, * p<0.05 versus 125 mM Na+ buffer.
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Effect of CTL knockdown on choline transport and ACh secretion. CTL subtypes 1–5 and
CHT1 were knocked-down by RNAi and cells processed as described in the methods. A.
Isoform specific siRNAs decreased levels of CTL1, 2, 4 and 5 mRNA respectively by 50–
70% compared to control siRNA-treated cells without affecting levels of other CTL’s.
Knockdown for CHT1 and CTL3 are not shown since they were below the level of detection
in H82 cells and were included as negative controls for effects on ACh secretion. Data are
mean ± SE of at least four replicates in two separate experiments. *P < 0.05 compared to
RNA levels in cells treated with control (nonsense) siRNA. B. Choline uptake in Na+-free
buffer was significantly decreased compared to control siRNA in H82 cells by knockdown
of CTL 1, 2 or 5, but not by knockdown of CTL4 (control choline uptake equaled 10.04 ±
1.66 pmol/mg/15min, choline concentration = 20 nM). Data are mean ± SE of 4 replicates in
two separate experiments. *P < 0.05 compared to choline uptake in cells treated with control
siRNA. C. Effect of knockdown of CTLs 1–5 and CHT1 on ACh secretion by H82 cells.
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Only knockdown of CTL4 significantly reduced ACh secretion CTL4 (control ACh
secretion equaled 80.2 ± 29.9 pmol/0.5 million cells/24h). Knockdown of CTL3, 5 and
CHT1 had no effect, while knockdown of CTL1 and 2 significantly increased levels of ACh
secretion. 50 μM neostigmine added to all cultures to prevent ACh degradation. Data are
mean ± SE of 6 replicates in three separate experiments. *P <0.05 compared to the cells
treated with control siRNA.
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CTL4 expression in H82 cells increased choline transport and ACh synthesis. Lentivirus
CTL4 vector construction and transduction as described in the material and methods. A.
CTL4 transduction increased choline uptake by H82 cells. Data are mean ± SE of 6
replicates in three separate experiments. *P< 0.05 compared to control vector. B. CTL4
transduction significantly increased ACh synthesis in H82 cells. Data are mean ± SE of 4
replicates in two separate experiments. 50 μM neostigmine added to all cultures to prevent
ACh degradation. Cell number was also measured at 24 hours and was not affected by
lentivirus transduction (data not shown). * P<0.05 compared to control vector. C.
Transduction of H82 cells with CTL4 lentivirus increased levels of CTL4 more than 200-
fold compared to cells transduced with a control lentivirus. Other CTL’s and ChAT were not
significantly changed.
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CTL4 modulates ACh synthesis in colon cancer cells. A. Expression of CTL1 in colon and
lung cancer cell lines. B. Expression of CTL4 in colon and lung cancer cell lines. C.Effect
of knockdown of CTLs 1, 4 and CHT1 on ACh synthesis of H508 cells. Specific siRNAs
decreased levels of CTL1 and CTL4 mRNA respectively by 50–60% compared to control
siRNA-treated cells (data not shown, but similar knockdown and specificity as shown in
figure 3). Data are mean ± SE of 7 replicates in two separate experiments and show percent
of control intracellular ACh (0.07 pmol by 100,000 H508 cells treated with control siRNA)
or percent of control media ACh concentration (0.14 pmol per 100,000 H508 cells treated
with control siRNA in 48 h). *p < 0.01versus control siRNA. 50 μM neostigmine added to
all cultures to prevent ACh degradation. D. CTL4 transduction increased ACh synthesis by
Caco-2 cells. Transduction of CTL4 significantly elevated intracellular ACh of Caco-2 cells
by 35%, but did not significantly impact ACh secretion. Data are mean ± SE of 10 replicates
in two separate experiments and presented as percentage of Caco-2 cells ACh secretion by
cells transduced with control lentivirus or ACh secretion (1.76 pmol by 100,000 Caco-2
cells within 48 h) or percent of intracellular ACh in cell cells transduced with control
lentivirus (3.91 pmol in 100,000 Caco-2 cells). 50 μM neostigmine added to all cultures to
prevent ACh degradation. Right hand bars show that CTL4 transduction increased CTL4
mRNA levels 9.1-fold compared to cells transduced with control lentivirus, but did not
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significantly affect levels of the other CTL or ChAT mRNA. *p < 0.01 versus control
lentivirus.
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Modulation of SCLC cell growth by choline and cholinergic receptor antagonists. H82 cells
were plated as described in the material and methods. Drugs were added immediately after
plating cells and incubated for 9 days as described in methods. A. Choline caused a
concentration-dependent increase of H82 cell proliferation at 9 days (* P < 0.05). B. The
mAChR antagonist atropine at 1 and 10 μM inhibited the increase of H82 cell proliferation
induced by increased choline (320 μM). C. The nAChR antagonist mecamylamine at 1 and
10 μM inhibited the increase of H82 cell proliferation induced by increased choline (320
μM). Data were mean ± SE of 12 replicates in two separate experiments. * p< 0.05 versus
baseline choline. † p<0.05 versus 320 μM choline alone. chol, choline; Atr, atropine; Mec,
Song et al. Page 20













mecamylamine. D. Effect of CTL knockdown on H82 cell growth (choline concentration =
20 μM). Consistent with the effects of CTL knockdowns on ACh secretion shown in panel
C, knockdown of CTL4 significantly decreased H82 cell growth while knockdown of CTL5
had no effect and knockdown of CTL1 had a small stimulatory effect. Data were mean ± SE
of 20 replicates in two separate experiments. *P<0.05 compared to the cells treated with
control siRNA. E., F. Increased levels of choline did not affect levels of CTL expression in
either H82 or H508 cells.
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